Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Transparency Is Still A Problem As Big Pharma Struggles With Its Image

“Reputation, built on our past, shapes our present and future. A good reputation can open many doors; a bad reputation can close many more. A good reputation generates respect. A bad reputation breeds suspicion.” Those are not the words of a business consultant or from a television talk show host like Dr. Phil. They are […]

Read More »

IBM’s Watson to guide cancer therapies at 14 centers

  (Reuters) – Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp’s (IBM.N) Watson computer system to choose therapies based on a tumor’s genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Oncology is the first specialty where matching therapy to DNA has […]

Read More »

VIVUS Reports First Quarter 2015 Financial Results

MOUNTAIN VIEW, CA–(Marketwired – May 05, 2015) – VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2015. “We have sharpened […]

Read More »

As Hampton Takes Over as Chairman at GlaxoSmithKline (GSK), CEO Witty Needs to Deliver or “Step Aside”

GlaxoSmithKline (GSK) is under scrutiny Tuesday, after more analysts have called for its longstanding chief executive, Sir Andrew Witty, to either step up his performance or resign within the next year, as the company prepares to receive its new chairman later this week. “Mr. Witty is running out of time,” said Stephen Bailey, a fund […]

Read More »

IBM Closes Acquisition of Phytel

ARMONK, N.Y. and DALLAS, May 4, 2015 /PRNewswire/ — IBM (NYSE: IBM) today announced it has completed the acquisition of Phytel, a leading provider of integrated population health management software based in Dallas, Texas. Financial terms of the deal were not disclosed. Phytel is a leader in physician-led population health management software that develops and […]

Read More »

Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis

Antisense Approach for Clotting Disorders Whippany, NJ – WEBWIRE – Monday, May 04, 2015 Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in […]

Read More »

Bayer buys rights to Isis Pharma’s anti-clotting drug

(Reuters) – German drugmaker Bayer secured the rights to an experimental anti-blood-clotting drug in a deal with California-based Isis Pharmaceuticals to bolster its cardiovascular business led by blockbuster pill Xarelto. Bayer plans to evaluate the blood-thinning drug, called ISIS-FXI, in frail patients that cannot be given currently available drugs because they are at high risk […]

Read More »

Tiny Corbus looks to take on Vertex with experimental lung drug

(Reuters) – Corbus Pharmaceuticals Holdings Inc’s experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc’s successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab, and expects […]

Read More »

Costco Accuses Johnson & Johnson (JNJ) of Price Fixing

Costco Wholesale Corp. filed a complaint in March against Johnson & Johnson (JNJ), accusing J&J’s Vision Care Inc. of price fixing related to its contact lenses. The suit was made public on Friday in J&J’s quarterly report to the U.S. Securities and Exchange Commission (SEC). J&J’s 10-Q filing has a laundry list of updates on […]

Read More »

New Company to Develop Vaccines, Discovered by City of Hope Researchers, to Protect Against CMV Infections in Cancer Patients

DUARTE, Calif.–(BUSINESS WIRE)–City of Hope and Fortress Biotech have reached an agreement to form a new subsidiary company, DiaVax Biosciences, that will develop two novel vaccines against cytomegalovirus infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. Enlisting the defensive power of the immune system, […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom